Indaptus Therapeutics, Inc. Net Income
Indaptus Therapeutics, Inc. (INDP) reported Net Income of -$1.79 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-08-13
- Indaptus Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$1.79M.
- Indaptus Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$2.54M.
- Indaptus Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$8.11M.
- Indaptus Therapeutics, Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$2.98M.
- Indaptus Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2022 was -$14.32M.
- Indaptus Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2021 was -$7.71M.
- Indaptus Therapeutics, Inc. net income (loss) attributable to parent for fiscal 2020 was -$3.58M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 6 month as first filed | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$1.79M 10-Q · filed 2026-08-13 | -$4.34M 10-Q · filed 2026-08-13 | -$12.45M derived: sum of 3 quarters · filed 2026-08-13 | -$15.42M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | -$2.54M 10-Q · filed 2026-08-13 | -$10.65M derived: sum of 2 quarters · filed 2026-08-13 | -$13.63M derived: sum of 3 quarters · filed 2026-08-13 | -$18.86M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | -$8.11M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-07-16 | -$11.09M derived: sum of 2 quarters · filed 2026-07-16 | -$16.32M derived: sum of 3 quarters · filed 2026-08-13 | -$20.85M DEF 14A · filed 2026-07-16 | ||
| 2025-09-30 | -$2.98M 10-Q · filed 2025-11-12 | -$8.20M derived: sum of 2 quarters · filed 2026-08-13 | -$12.74M 10-Q · filed 2025-11-12 | -$16.87M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | -$5.23M 10-Q · filed 2026-08-13 | -$9.76M 10-Q · filed 2026-08-13 | -$13.89M derived: sum of 3 quarters · filed 2026-08-13 | -$16.96M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | -$4.53M 10-Q · filed 2026-08-13 | -$8.66M derived: sum of 2 quarters · filed 2026-08-13 | -$11.73M derived: sum of 3 quarters · filed 2026-08-13 | -$15.75M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2024-12-31 | -$4.13M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-07-16 | -$7.20M derived: sum of 2 quarters · filed 2026-07-16 | -$11.22M derived: sum of 3 quarters · filed 2026-07-16 | -$15.02M DEF 14A · filed 2026-07-16 | ||
| 2024-09-30 | -$3.07M 10-Q · filed 2025-11-12 | -$7.08M derived: sum of 2 quarters · filed 2025-11-12 | -$10.89M 10-Q · filed 2025-11-12 | -$14.89M derived: sum of 4 quarters · filed 2026-07-16 | ||
| 2024-06-30 | -$4.02M 10-Q · filed 2025-11-12 | -$7.82M 10-Q · filed 2025-08-13 | -$11.82M derived: sum of 3 quarters · filed 2026-07-16 | -$15.75M derived: sum of 4 quarters · filed 2026-07-16 | ||
| 2024-03-31 | -$3.81M 10-Q · filed 2025-11-12 | -$7.81M derived: sum of 2 quarters · filed 2026-07-16 | -$11.73M derived: sum of 3 quarters · filed 2026-07-16 | -$14.98M derived: sum of 4 quarters · filed 2026-07-16 | ||
| 2023-12-31 | -$4.00M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-07-16 | -$7.93M derived: sum of 2 quarters · filed 2026-07-16 | -$11.17M derived: sum of 3 quarters · filed 2026-07-16 | -$15.42M DEF 14A · filed 2026-07-16 | ||
| 2023-09-30 | -$3.92M 10-Q · filed 2024-11-12 | -$7.17M derived: sum of 2 quarters · filed 2024-11-12 | -$11.42M 10-Q · filed 2024-11-12 | -$15.08M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | -$3.25M 10-Q · filed 2024-11-12 | -$7.50M 10-Q · filed 2024-08-12 | -$11.15M derived: sum of 3 quarters · filed 2024-11-12 | -$14.62M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-03-31 | -$4.25M 10-Q · filed 2024-11-12 | -$7.91M derived: sum of 2 quarters · filed 2024-11-12 | -$11.38M derived: sum of 3 quarters · filed 2024-11-12 | -$15.21M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2022-12-31 | -$3.66M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$7.12M derived: sum of 2 quarters · filed 2024-03-13 | -$10.96M derived: sum of 3 quarters · filed 2024-03-13 | -$14.32M 10-K · filed 2024-03-13 | ||
| 2022-09-30 | -$3.47M 10-Q · filed 2023-11-06 | -$7.30M derived: sum of 2 quarters · filed 2023-11-06 | -$10.67M 10-Q · filed 2023-11-06 | -$13.88M derived: sum of 4 quarters · filed 2023-11-06 | ||
| 2022-06-30 | -$3.84M 10-Q · filed 2023-11-06 | -$7.20M 10-Q · filed 2023-08-14 | -$10.42M derived: sum of 3 quarters · filed 2023-11-06 | -$13.78M derived: sum of 4 quarters · filed 2023-11-06 | ||
| 2022-03-31 | -$3.37M 10-Q · filed 2023-11-06 | -$6.58M derived: sum of 2 quarters · filed 2023-11-06 | -$9.95M derived: sum of 3 quarters · filed 2023-11-06 | -$10.46M derived: sum of 4 quarters · filed 2023-11-06 | ||
| 2021-12-31 | -$3.22M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | -$6.58M derived: sum of 2 quarters · filed 2023-03-17 | -$7.10M derived: sum of 3 quarters · filed 2023-03-17 | -$7.71M 10-K · filed 2023-03-17 | ||
| 2021-09-30 | -$3.37M 10-Q · filed 2022-11-10 | -$3.88M derived: sum of 2 quarters · filed 2022-11-10 | -$4.50M 10-Q · filed 2022-11-10 | -$5.27M derived: sum of 4 quarters · filed 2022-11-10 | ||
| 2021-06-30 | -$515.48K 10-Q · filed 2022-11-10 | -$7.43M 10-Q · filed 2021-08-16 | -$1.13M 10-Q · filed 2022-08-08 | -$11.66M 10-Q · filed 2021-08-16 | -$1.90M derived: sum of 3 quarters · filed 2022-11-10 | -$3.44M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-03-31 | -$612.42K 10-Q · filed 2022-11-10 | -$1.38M derived: sum of 2 quarters · filed 2022-11-10 | -$2.93M derived: sum of 3 quarters · filed 2022-11-10 | -$3.64M derived: sum of 4 quarters · filed 2022-11-10 | ||
| 2020-12-31 | -$770.22K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$2.31M derived: sum of 2 quarters · filed 2022-03-21 | -$3.03M derived: sum of 3 quarters · filed 2022-03-21 | -$3.58M 10-K · filed 2022-03-21 | ||
| 2020-09-30 | -$1.54M 10-Q · filed 2021-11-15 | -$2.26M derived: sum of 2 quarters · filed 2021-11-15 | -$2.81M 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | -$712.62K 10-Q · filed 2021-11-15 | -$2.95M 10-Q · filed 2021-08-16 | -$6.82M 10-Q · filed 2021-08-16 | |||
| 2020-03-31 | -$558.58K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |